Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Jorne L Biccler, a Department of Haematology , Aalborg University Hospital , Aalborg , Denmark., b Department of Clinical Medicine, Faculty of Medicine , Aalborg University , Aalborg , Denmark.
  • ,
  • Kerry J Savage, c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.
  • ,
  • Peter D N Brown, d Department of Haematology , Copenhagen University Hospital , Copenhagen, Denmark.
  • ,
  • Judit Jørgensen, e Department of Haematology , Aarhus University Hospital , Aarhus , Denmark.
  • ,
  • Thomas S Larsen, f Department of Haematology , Odense University Hospital , Odense , Denmark.
  • ,
  • Christian B Poulsen
  • Danny Stoltenberg, h Department of Haematology , Herlev and Gentofte Hospital , Copenhagen, Denmark.
  • ,
  • Laurie H Sehn, c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.
  • ,
  • David W Scott, c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.
  • ,
  • Alina S Gerrie, c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.
  • ,
  • Lasse H Jakobsen, b Department of Clinical Medicine, Faculty of Medicine , Aalborg University , Aalborg , Denmark.
  • ,
  • Martin Bøgsted
  • Tarec C El-Galaly, a Department of Haematology , Aalborg University Hospital , Aalborg , Denmark., b Department of Clinical Medicine, Faculty of Medicine , Aalborg University , Aalborg , Denmark.
  • ,
  • Diego Villa, c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.

In this study, we analyzed the evolution of the prognosis of primary central nervous system lymphoma (PCNSL) patients as they reach selected progression-free survival (PFS) milestones after high-dose methotrexate (HD-MTX)-based therapy. In total, 258 and 146 patients were included from Denmark and British Columbia, respectively. All patients were diagnosed during 2000-2017. The 5-year PFS was 27% (95% CI 23; 32); however, for patients reaching 5 years of PFS, this increased to 71% (95% CI 57; 86). Within the first 5 years after diagnosis, patients lost 2.0 years (95% CI 1.8; 2.2) when compared to a similar background population. This reduced to 0.5 years (95% CI 0.2; 0.9) for patients reaching 5 years of PFS. Treatment with rituximab was associated with improved outcomes. The prognosis of patients with PCNSL treated with HD-MTX-based regimens in this cohort is poor, although it improves as patients survive without progression/relapse. However, survival does not conclusively normalize to that of a similar background population.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Sider (fra-til)1-8
Antal sider8
ISSN1042-8194
DOI
StatusE-pub ahead of print - 3 apr. 2019
Eksternt udgivetJa

Se relationer på Aarhus Universitet Citationsformater

ID: 154488607